Grace Health Technology Launches New Laboratory Management Software
Live Sample Management Application Streamlines Laboratory Operations Software for Enhanced Laboratory Data Management Efficiency Secures HIPAA Protected and Financial Laboratory...
Day: March 29, 2024
Avenues Recovery Center to Open at South Bend
Avenues Recovery is set to open a brand-new, 120-bed facility in Mishawaka, IndianaMISHAWAKA, IN / ACCESSWIRE / March 29, 2024...
Bristol Myers Squibb Expands Health Equity Grant Initiatives to Improve Health Outcomes
Company Awards $1.8M in Grants to Eight Organizations in Brazil, India, Thailand and the United KingdomOriginally published on Bristol Myers...
Universal Recall Platform Alliance Launches to Keep Patients Safe
Industry initiative URPA broadens calls to improve speed, accuracy of recall communicationWEST HOLLYWOOD, CA / ACCESSWIRE / March 29, 2024...
Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates
ELI-002 2P clinical immunogenicity data were accepted for a poster presentation at the AACR Annual Meeting 2024ELI-007 and ELI-008 preclinical...
Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update
AUSTIN, Texas, March 29, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company...
KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
-- Advancing ongoing Phase 2b CHASE trial of KPI-012 for PCED; topline data targeted by year-end 2024 ---- Exploring opportunities...
Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update
NORCROSS, Ga., March 29, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target...
SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results
Sioux Falls, SD , March 29, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results...
Vision Sensing Acquisition Corp. Announces Intention to Extend Period to Consummate Initial Business Combination to May 3, 2024
MIAMI, March 29, 2024 (GLOBE NEWSWIRE) -- Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW) (the “Company”) a special purpose...
Guardion Health Sciences Announces Financial Results for the Year Ended December 31, 2023
Viactiv® Product Line Generated Net Revenues of Approximately $11.9 Million for the Year Ended December 31, 2023, an Increase of...
Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, March 29, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or...
BioSenic S.A. : Information on the total number of voting rights and shares
PRESS RELEASE – REGULATED INFORMATION Mont-Saint-Guibert, Belgium, March 29, 2024, 7.00 am CEST – BIOSENIC (Euronext Brussels and Paris: BIOS),...
Junshi Biosciences Announces 2023 Full Year Financial Results and Provides Corporate Updates
SHANGHAI, China, March 29, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a...
Trinity Biotech plc to Announce Q4 and Fiscal Year 2023 Financial Results
Conference Call Scheduled for Thursday, April 4, 2024 at 8:00 AM ETDUBLIN, Ireland, March 28, 2024 (GLOBE NEWSWIRE) -- Trinity...
Predictive Oncology Reports Year End 2023 Financial Results and Provides Business Update
Company to host investor call and webcast on Monday, April 1st, at 8:30am EDTPITTSBURGH, March 28, 2024 (GLOBE NEWSWIRE) --...
Burning Rock Reports Fourth Quarter and Full Year 2023 Financial Results
GUANGZHOU, China, March 28, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or...
Sirona Biochem Announces 2023 Annual Meeting Results
VANCOUVER, British Columbia, March 28, 2024 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) announces...
Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
Launch of OLPRUVA® underway Topline results from KP1077 phase 2 study demonstrate clinically meaningful benefits for key IH symptoms Q4...
Applied Therapeutics Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic Galactosemia
NEW YORK, March 28, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline...